Soler et al. suggest that the levels of EphA4 may be controlled by ERBB3/HER3, a prostate cancer-associated receptor, as knockdown of ERBB3 in DU-145 cells resulted in EphA4 downregulation [68]. This evidence concerns the gene EPHA4 and prostate carcinoma.